Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

New survival standards for advanced melanoma.

Spain L, Larkin J, Turajlic S.

Br J Cancer. 2020 Feb 17. doi: 10.1038/s41416-020-0738-5. [Epub ahead of print] No abstract available.

PMID:
32063602
2.

Evolution of Renal Cell Carcinoma.

Tippu Z, Au L, Turajlic S.

Eur Urol Focus. 2020 Jan 29. pii: S2405-4569(19)30383-9. doi: 10.1016/j.euf.2019.12.005. [Epub ahead of print] Review.

PMID:
32007485
3.

Author Correction: Resolving genetic heterogeneity in cancer.

Turajlic S, Sottoriva A, Graham T, Swanton C.

Nat Rev Genet. 2020 Jan;21(1):65. doi: 10.1038/s41576-019-0188-1.

PMID:
31659302
4.

How we treat neurological toxicity from immune checkpoint inhibitors.

Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S.

ESMO Open. 2019 Jul 31;4(Suppl 4):e000540. doi: 10.1136/esmoopen-2019-000540. eCollection 2019. Review.

5.

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.

O'Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, Mclean E, Edmonds K, Lingard K, Chauhan D, Lynch J, Au L, Ludlow A, Pattison N, Wiseman T, Turajlic S, Gore M, Larkin J, Husson O.

Support Care Cancer. 2020 Feb;28(2):561-570. doi: 10.1007/s00520-019-04818-w. Epub 2019 May 14.

6.

Resolving genetic heterogeneity in cancer.

Turajlic S, Sottoriva A, Graham T, Swanton C.

Nat Rev Genet. 2019 Jul;20(7):404-416. doi: 10.1038/s41576-019-0114-6. Review. Erratum in: Nat Rev Genet. 2020 Jan;21(1):65.

PMID:
30918367
7.

Standing on the shoulders of giants.

Turajlic S.

Nat Med. 2019 Mar;25(3):357. doi: 10.1038/s41591-019-0389-3. No abstract available.

PMID:
30842663
8.

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma.

Shepherd STC, Litchfield K, Turajlic S.

Ann Oncol. 2019 Mar 1;30(3):355-357. doi: 10.1093/annonc/mdz042. No abstract available.

9.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
10.

Kidney cancer: The next decade.

Turajlic S, Swanton C, Boshoff C.

J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14.

11.

Immunotherapy for Melanoma Metastatic to the Brain.

Turajlic S, Larkin J.

N Engl J Med. 2018 Aug 23;379(8):789-790. doi: 10.1056/NEJMe1807752. No abstract available.

PMID:
30134137
12.

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.

Flynn M, Pickering L, Larkin J, Turajlic S.

Ther Adv Med Oncol. 2018 Jun 12;10:1758835918777427. doi: 10.1177/1758835918777427. eCollection 2018. Review.

13.

Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O'Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, Hazell S, Eichler-Jonsson C, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Jabbar F, Spain L, Lall S, Guarch R, Falzon M, Proctor I, Pickering L, Gore M, Watkins TBK, Ward S, Stewart A, DiNatale R, Becerra MF, Reznik E, Hsieh JJ, Richmond TA, Mayhew GF, Hill SM, McNally CD, Jones C, Rosenbaum H, Stanislaw S, Burgess DL, Alexander NR, Swanton C; PEACE; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):581-594.e12. doi: 10.1016/j.cell.2018.03.057. Epub 2018 Apr 12.

14.

Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.

Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, Au L, Eichler-Jonsson C, Jabbar F, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Stewart A, Xing W, Smith JC, Escudero M, Huffman A, Matthews N, Elgar G, Phillimore B, Costa M, Begum S, Ward S, Salm M, Boeing S, Fisher R, Spain L, Navas C, Grönroos E, Hobor S, Sharma S, Aurangzeb I, Lall S, Polson A, Varia M, Horsfield C, Fotiadis N, Pickering L, Schwarz RF, Silva B, Herrero J, Luscombe NM, Jamal-Hanjani M, Rosenthal R, Birkbak NJ, Wilson GA, Pipek O, Ribli D, Krzystanek M, Csabai I, Szallasi Z, Gore M, McGranahan N, Van Loo P, Campbell P, Larkin J, Swanton C; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):595-610.e11. doi: 10.1016/j.cell.2018.03.043. Epub 2018 Apr 12.

15.

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):611-623.e17. doi: 10.1016/j.cell.2018.02.020. Epub 2018 Apr 12.

16.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.

17.

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma.

Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, Turajlic S, Board R, Larkin JM, Lorigan P.

ESMO Open. 2018 Feb 24;3(2):e000317. doi: 10.1136/esmoopen-2017-000317. eCollection 2018.

18.

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.

Turajlic S, Gore M, Larkin J.

Ann Oncol. 2018 Mar 1;29(3):542-543. doi: 10.1093/annonc/mdy020. No abstract available.

19.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
20.

The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released.

Litchfield K, Turajlic S, Swanton C.

Cancer Discov. 2017 Aug;7(8):796-798. doi: 10.1158/2159-8290.CD-17-0604.

21.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C.

Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7.

22.

Implications of cancer evolution for drug development.

Turajlic S, Swanton C.

Nat Rev Drug Discov. 2017 Jul;16(7):441-442. doi: 10.1038/nrd.2017.78. Epub 2017 Apr 28. No abstract available.

PMID:
28450743
23.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

24.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

25.

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.

Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J.

Ann Oncol. 2017 Feb 1;28(2):377-385. doi: 10.1093/annonc/mdw558. Review.

26.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

27.

Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.

Spain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J.

Cancer Immunol Immunother. 2017 Jan;66(1):113-117. doi: 10.1007/s00262-016-1926-2. Epub 2016 Nov 12.

PMID:
27838762
28.

Systemic treatment of advanced papillary renal cell carcinoma: Where next?

Turajlic S, Larkin J.

Eur J Cancer. 2016 Dec;69:223-225. doi: 10.1016/j.ejca.2016.10.002. Epub 2016 Nov 4. No abstract available.

PMID:
27825560
29.

Metastasis as an evolutionary process.

Turajlic S, Swanton C.

Science. 2016 Apr 8;352(6282):169-75. doi: 10.1126/science.aaf2784. Review.

PMID:
27124450
30.

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.

Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J.

Ann Oncol. 2016 Jun;27(6):1135-7. doi: 10.1093/annonc/mdw130. Epub 2016 Mar 6.

31.

SnapShot: Renal Cell Carcinoma.

Turajlic S, Larkin J, Swanton C.

Cell. 2015 Dec 3;163(6):1556-1556.e1. doi: 10.1016/j.cell.2015.11.026.

32.

Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy.

Turajlic S, Swanton C.

Nat Rev Clin Oncol. 2015 Oct;12(10):565-6. doi: 10.1038/nrclinonc.2015.153. Epub 2015 Sep 8. No abstract available.

PMID:
26346844
33.

Relapse models for clear cell renal carcinoma.

Gulati S, Turajlic S, Larkin J, Bates PA, Swanton C.

Lancet Oncol. 2015 Aug;16(8):e376-8. doi: 10.1016/S1470-2045(15)00090-X. No abstract available.

PMID:
26248843
34.

Academically led clinical trials: challenges and opportunities.

Turajlic S, Larkin J, Swanton C.

Ann Oncol. 2015 Oct;26(10):2010-1. doi: 10.1093/annonc/mdv332. Epub 2015 Aug 3. No abstract available.

35.

How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?

Soultati A, Stares M, Swanton C, Larkin J, Turajlic S.

Curr Opin Urol. 2015 Sep;25(5):358-66. doi: 10.1097/MOU.0000000000000204. Review.

PMID:
26125509
36.

Inferring mutational timing and reconstructing tumour evolutionary histories.

Turajlic S, McGranahan N, Swanton C.

Biochim Biophys Acta. 2015 Apr;1855(2):264-75. doi: 10.1016/j.bbcan.2015.03.005. Epub 2015 Mar 27. Review.

37.

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.

Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, Gavrielides M, Xing W, Gore M, Larkin J, Marais R.

Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8. doi: 10.1111/pcmr.12279. Epub 2014 Jun 30.

PMID:
24913711
38.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R.

Sci Signal. 2014 Mar 25;7(318):ra30. doi: 10.1126/scisignal.2004815.

PMID:
24667377
39.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.

Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.

40.

SF3B1 mutations are associated with alternative splicing in uveal melanoma.

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R.

Cancer Discov. 2013 Oct;3(10):1122-1129. doi: 10.1158/2159-8290.CD-13-0330. Epub 2013 Jul 16.

41.

Phase I/II RAF kinase inhibitors in cancer therapy.

Turajlic S, Ali Z, Yousaf N, Larkin J.

Expert Opin Investig Drugs. 2013 Jun;22(6):739-49. doi: 10.1517/13543784.2013.797964. Epub 2013 May 6. Review.

PMID:
23642225
42.

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.

Furney SJ, Turajlic S, Stamp G, Nohadani M, Carlisle A, Thomas JM, Hayes A, Strauss D, Gore M, van den Oord J, Larkin J, Marais R.

J Pathol. 2013 Jul;230(3):261-9. doi: 10.1002/path.4204.

PMID:
23620124
43.

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Khattak M, Fisher R, Turajlic S, Larkin J.

Ther Adv Med Oncol. 2013 Mar;5(2):105-18. doi: 10.1177/1758834012466280.

44.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.

Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.

45.

Genomic characterisation of acral melanoma cell lines.

Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R.

Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x.

PMID:
22578220
46.

Whole genome sequencing of matched primary and metastatic acral melanomas.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R.

Genome Res. 2012 Feb;22(2):196-207. doi: 10.1101/gr.125591.111. Epub 2011 Dec 19.

47.

Generalized melanosis and melanuria in a patient with metastatic melanoma.

Perez A, Turajlic S, Szyszko T, O'Doherty M, Calonje E, Harries M, Acland K.

Clin Exp Dermatol. 2010 Apr;35(3):e37-9. doi: 10.1111/j.1365-2230.2009.03545.x. No abstract available.

PMID:
20500171

Supplemental Content

Loading ...
Support Center